Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 180 clinical trials
Featured trial
A Phase III, randomized, double-blind, placebo controlled, multicenter study to evaluate the efficacy and safety of Etrolizumab as an induction and maintenance treatment for patients with moderately to severe active Crohn's Disease.

A Phase III, randomized, double-blind, placebo controlled, multicenter study to evaluate the efficacy and safety of Etrolizumab as an induction and maintenance treatment for patients with moderately to severe active Crohn's Disease.

  • 180 views
  • 25 Mar, 2021
  • 1 location
Featured trial
A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

  • 2446 views
  • 23 Nov, 2020
  • 18 locations
  • 0 views
  • 20 Sep, 2022
  • 89 locations
RA-PRO PRAGMATIC TRIAL (RA-PROPR)

The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing

DMARD
prednisone
baricitinib
abatacept
leflunomide
  • 0 views
  • 28 Jun, 2022
  • 1 location
A Phase 2 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lutikizumab (ABT-981) in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

, under armpits, inner thighs, groin and buttocks. Despite the clinical benefit anti-tumor necrosis factor (TNF) therapy offers to patients with HS, there remains a significant unmet medical need for

abscess
  • 46 views
  • 22 Sep, 2022
  • 45 locations
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe ulcerative colitis will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission after treatment with vedolizumab. Remission …

vedolizumab
corticosteroids
tumour necrosis
tumor necrosis factor alpha
proctitis
  • 0 views
  • 19 Sep, 2022
  • 62 locations
Exercise-induced Cardiac Adaptions in Rheumatoid Arthritis Patients During Interleukin-6 vs. Tumor Necrosis Factor Antibody Therapy (RABEX)

The present study will investigative the physiological effects of the cytokines interleukin-6 (IL-6) and tumor necrosis factor (TNF) on the adaptive changes to exercise in patients with

Accepts healthy volunteers
tumour necrosis
tumor necrosis factor
  • 0 views
  • 10 Mar, 2022
  • 1 location
Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation (GO-GUT)

as more need to use anti-tumor necrosis factor therapy and a shorter time to relapse after stopping anti-tumor necrosis factor therapy after obtaining sustained clinical remission. Overall, the

tumor necrosis factor
golimumab
factor a
back pain
hla-b27
  • 3 views
  • 03 Feb, 2022
  • 3 locations
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis (AFFINITY)

prior anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy by assessing clinical response compared with guselkumab monotherapy.

infliximab
psoriatic plaque
psoriasis
rheumatoid nodules
tumour necrosis
  • 7 views
  • 25 Jul, 2022
  • 16 locations
Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis

This randomized pragmatic trial will generate knowledge about strategies used to de-escalate tumor necrosis factor inhibitor (TNFi) therapy in patients with juvenile spondyloarthritis with

  • 0 views
  • 08 Jan, 2022
  • 1 location